Loading...
•
Dec 31, 2023
Arcellx Q4 2023 Earnings Report
Arcellx reported fourth quarter and year-end financial results, highlighted by an expanded strategic partnership with Kite and robust long-term responses from the Phase 1 expansion trial of anito-cel.
Key Takeaways
Arcellx reported collaboration revenue of $63.1 million for the fourth quarter of 2023 and ended the quarter with $729.2 million in cash, cash equivalents, and marketable securities, extending the cash runway into 2027. Net income for the quarter was $20.5 million.
Expanded strategic partnership with Kite Pharma, Inc. to include co-development of anito-cel for lymphomas and Kite exercising its option to license ACLX-001.
Presented continued robust long-term responses from lead product candidate anito-cel evaluated in a Phase 1 expansion trial in patients with relapsed or refractory multiple myeloma, at 65th ASH Annual Meeting and Exposition.
Ended the quarter with $729.2 million in cash, extending cash runway into 2027.
Collaboration revenue was $63.1 million for the quarter.
Forward Guidance
Arcellx anticipates that its cash, cash equivalents, and marketable securities will fund its operations into 2027.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...